Related Experiment Video
Updated: Nov 18, 2025
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.7K
Reduced melanoma referrals during COVID-19 lockdown
William Berry1, Katrina Tan2, Andrew Haydon3
1MBBS, BMedSc, PhD, Clinical Fellow, Victorian Melanoma Service, Alfred Health Melbourne, Vic; Post-doctoral Research Fellow, Central Clinical School, Monash University, Melbourne, Vic.
Australian Journal of General Practice
|February 5, 2021
Summary
The COVID-19 pandemic likely reduced early melanoma diagnoses and delayed the detection of advanced cases due to fewer in-person medical visits.
Area of Science:
- Dermatology and Oncology
- Epidemiology
Background:
- The COVID-19 pandemic significantly altered healthcare delivery, reducing in-person medical consultations globally.
- This shift raised concerns about its impact on the timely diagnosis of various medical conditions, including skin cancers.
Purpose of the Study:
- To investigate the anticipated effects of reduced medical consultations during the COVID-19 pandemic on melanoma diagnosis rates.
- To assess the potential for delayed presentation of both thin (early-stage) and thick (advanced-stage) melanomas.
Main Methods:
- Retrospective analysis of diagnostic data.
- Comparison of melanoma diagnostic trends before and during the pandemic.
- Focus on changes in the proportion of thin versus thick melanoma presentations.
Main Results:
- Anticipated reduction in the diagnosis of thin melanomas.
- Anticipated increase in the delayed presentation of thick melanomas.
- The pandemic's impact on early detection and advanced disease presentation requires further investigation.
Conclusions:
- The reduction in face-to-face consultations during the COVID-19 pandemic was expected to negatively impact melanoma detection rates.
- A potential delay in the presentation of thick melanomas was a significant concern.
- Monitoring diagnostic trends is crucial for understanding and mitigating the long-term consequences of pandemic-related healthcare disruptions on cancer outcomes.
